Public Release: 

New role of protein kinases in embryo development and cancer

A group of protein kinases have been found to play an important role in embryo development and may even be a potential cancer drug target, says research led by Queen Mary University of London and the Francis Crick Institute

Queen Mary, University of London

A group of protein kinases have been found to play an important role in embryo development and may even be a potential cancer drug target, says research led by Queen Mary University of London (QMUL) and the Francis Crick Institute, UK.

The study, published in Cell Reports, is the first description of knockouts of a whole family of protein kinases (PKN1-3) in mice and reveals roles in congenital birth defects such as spina bifida.

The team knocked out a whole kinase family but, unusually, only one member (PKN2) appeared to be important in development and warrants renewed attention.

The authors add that many of the functions already attributed to PKN have been largely, and possibly incorrectly, attributed to other kinase families, and hope that their current work raises the profile of this understudied kinase family.

PKN proteins are increasingly being recognised as important drug targets in cancer, and the team are currently using their models to test whether these kinases could be a drug target in pancreatic and breast cancer.

Dr Angus Cameron from QMUL's Barts Cancer Institute said: "It is often the case that proteins such as these are essential in development but not in adulthood. Indeed, we've shown that there's a limited need for this entire class of targets in adult mice. This is a positive sign for drug development against this family of proteins, where its members have been highjacked in cancer."

Professor Peter Parker from the Francis Crick Institute concurs: "The prospects for therapeutics targeting this family are good, although further work will be required to fully elaborate dependencies in adults."

###

The research was funded by Cancer Research UK, Barts Cancer Institute, HEFCE, the Wellcome Trust, and the Royal Society.

For more information, please contact:

Joel Winston
Public Relations Manager (School of Medicine and Dentistry)
Queen Mary University of London
j.winston@qmul.ac.uk
Tel: +44 (0)20 7882 7943 / +44 (0)7970 096 188

Notes to the editor

Research Paper

Quetier et al.: "Knockout of the PKN family of Rho effector kinases reveals a non-redundant role for PKN2 in developmental mesoderm expansion."

Cell Reports - January 26, 2016 issue. Published online on January 7th 2016.

About Queen Mary University of London

Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.

A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research - in the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014).

We also offer something no other university can: a stunning self-contained residential campus in London's East End. As well as our home at Mile End, we have campuses at Whitechapel, Charterhouse Square and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields.

We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace based at Mile End.

QMUL has an annual turnover of £350m, a research income worth £100m, and generates employment and output worth £700m to the UK economy each year.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.